Drugs / CD19/CD22 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03185494 | Aug 2017 → Aug 2019 | B-cell adult acute lymphocytic leukemia, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma +1 | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD22 CAR T cells | “Autologous CD19/CD22 CAR T cells proliferated in vivo and were detected in the blood, bone marrow, and cerebrospinal fluid.” PMID 32245502 ↗ Apr 2020 |
| Action | Deplete | “Bispecific CD19/CD22 CAR T cells could trigger robust cytolytic activity against target cells.” PMID 32245502 ↗ Apr 2020 |
| Modality | Cell therapy | “Autologous CD19/CD22 CAR T cells proliferated in vivo and were detected in the blood, bone marrow, and cerebrospinal fluid.” PMID 32245502 ↗ Apr 2020 |
| Target | CD19 | “targeting both CD19 and CD22” PMID 32245502 ↗ Apr 2020 |
| Target | CD22 | “targeting both CD19 and CD22” PMID 32245502 ↗ Apr 2020 |